drugset
drugset / Trial / NCT03497715

Gamma Scintigraphy Study to Investigate Tablet Disintegration in Healthy Volunteers.

NCT03497715 ↗

Phase 1 Terminated 6 enrolled Reckitt Benckiser Healthcare (UK) Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The study will be an adaptive, 2 part, single dose, 5-way crossover gamma scintigraphy study in healthy subjects, to investigate the rate and site of tablet disintegration of various forms of Ibuprofen.

Timeline

Start
2015-04-14
Primary completion
2015-07-30
Completion
2015-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 400 mg Oral
Subject Ibuprofen Small molecule 512 mg Oral
Subject Ibuprofen Small molecule 684 mg Oral

Indications

No indication recorded.